Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 14/20 | 0.45 |
| ▸ | ITGB6 | P18564 | 9/20 | 0.45 |
| ▸ | ITGB8 | P26012 | 4/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.45 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.45 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20481334 | 0.88 | ITGAV (0.51) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL20481320 | 0.85 | ITGAV (0.52) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL20481082 | 0.83 | ITGAV (0.49) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL20481302 | 0.83 | ITGAV (0.50) | ITGAVITGB3ITGB6ITGB8ITGB1 | |
| Hydrochloric Acid SCHEMBL20481296 | 0.81 | ITGAV (0.47) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL20481242 | 0.81 | ITGAV (0.47) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL22223273 | 0.80 | ITGAV (0.54) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL20481098 | 0.79 | ITGAV (0.48) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL8333656 | 0.78 | ITGAV (0.55) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL20480976 | 0.78 | ITGAV (0.52) | ITGAVITGB3ITGB6ITGB8ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4159727-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2024-10-03 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| CN-116283977-A | Inhibitors of αvβ6 integrin | 莫菲克医疗股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-110573499-B | Inhibitors of αvβ6 integrin | 莫菲克医疗股份有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4159727-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Morphic Therapeutic, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2021-09-09 | — | — | US | disclosed |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2021-09-09 | — | — | US | disclosed |
| US-11046669-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046669-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11040955-B2 | Inhibitors of (alpha-v)(beta-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040955-B2 | Inhibitors of (alpha-v)(beta-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200157075-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200157075-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200087299-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-03-19 | — | — | US | disclosed |
| WO-2018160521-A2 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Lazuli, Inc. (US) | 2018-09-07 | — | — | WO | disclosed |
| US-20180244648-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2018-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB3 11/4885ITGB6 1/4885 |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB3 11/4885ITGB6 1/4885 |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB3 10/4885ITGB6 1/4885 |
| US-20200087299-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGAV, ITGA6 | ITGAV 2/4885ITGB3 10/4885ITGB6 1/4885 |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB3 12/4885ITGB6 1/4885 |
| US-20200157075-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB3 11/4885ITGB6 1/4885 |
| US-20180244648-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB3 11/4885ITGB6 1/4885 |
| US-11040955-B2 | Inhibitors of (alpha-v)(beta-6) integrin | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB3 11/4885ITGB6 1/4885 |
| US-11046669-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB3 12/4885ITGB6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.